Cell Biology International · 2008 · 10 citations · 15 references
Life SciencesMolecular BiologyPharmacologyCell SignalingInflammationSignal TransductionAnti-inflammatory PharmacologyEnzyme InhibitionInflammatory SignalingInsulin ResistancePlasma ProteinsGhrelin BiologyGhrelin SignalingMicrovascular ComplicationsOrexigenic SignalingPlasminogen Activator ReleasePlasminogen Activators
Plasminogen activator inhibitor type 1 (PAI-1), produced partly from liver is a risk factor for macrovascular and microvascular complications of diabetes. Ghrelin, a recently described orexigenic peptide hormone, attenuates PAI-1 induced by TNF-alpha in the human hepatoma cell line (HepG2). Exposure to TNF-alpha (1 ng/ml) for 24h caused a significant increase in PAI-1 mRNA expression and protein secretion, as evaluated by RT-PCR and ELISA, but pretreatment with ghrelin (1-100 ng/ml) inhibited both basal and TNF-alpha-induced PAI-1 release in a dose and time-dependent manner in HepG2. PDTC, selective NF-kappaB inhibitor, had no additive inhibitory effects with ghrelin. The results indicate that ghrelin inhibits both basal and TNF-alpha-induced PAI-1 production via NF-kappaB pathway in HepG2 cells, and suggest that the peptide plays a therapeutic role in atherosclerosis, especially in obese patients with insulin resistance, in whom ghrelin levels were reduced.
15
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Masayasu Kojima, Hiroshi Hosoda, Yukari Date et al. · Nature · 1999 · 8.5K citations
Ghrelin Enhances Appetite and Increases Food Intake in Humans
Alison Wren, Leighton Seal, Mark A. Cohen et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 2.4K citations · Full text